NUK - logo
E-viri
Celotno besedilo
Recenzirano
  • PET/MRI assessment of lung ...
    Biondetti, Pierpaolo; Vangel, Mark G.; Lahoud, Rita M.; Furtado, Felipe S.; Rosen, Bruce R.; Groshar, David; Canamaque, Lina G.; Umutlu, Lale; Zhang, Eric W.; Mahmood, Umar; Digumarthy, Subba R.; Shepard, Jo-Anne O.; Catalano, Onofrio A.

    European journal of nuclear medicine and molecular imaging, 06/2021, Letnik: 48, Številka: 6
    Journal Article

    Purpose To evaluate PET/MR lung nodule detection compared to PET/CT or CT, to determine growth of nodules missed by PET/MR, and to investigate the impact of missed nodules on clinical management in primary abdominal malignancies. Methods This retrospective IRB-approved study included 18F-FDG PET/MR in 126 patients. All had standard of care chest imaging (SCI) with diagnostic chest CT or PET/CT within 6 weeks of PET/MR that served as standard of reference. Two radiologists assessed lung nodules (size, location, consistency, position, and 18F-FDG avidity) on SCI and PET/MR. A side-by-side analysis of nodules on SCI and PET/MR was performed. The nodules missed on PET/MR were assessed on follow-up SCI to ascertain their growth (≥ 2 mm); their impact on management was also investigated. Results A total of 505 nodules (mean 4 mm, range 1–23 mm) were detected by SCI in 89/126 patients (66M:60F, mean age 60 years). PET/MR detected 61 nodules for a sensitivity of 28.1% for patient and 12.1% for nodule, with higher sensitivity for > 7 mm nodules (< 30% and > 70% respectively, p  < 0.05). 75/337 (22.3%) of the nodules missed on PET/MR (follow-up mean 736 days) demonstrated growth. In patients positive for nodules at SCI and negative at PET/MR, missed nodules did not influence patients’ management. Conclusions Sensitivity of lung nodule detection on PET/MR is affected by nodule size and is lower than SCI. 22.3% of missed nodules increased on follow-up likely representing metastases. Although this did not impact clinical management in study group with primary abdominal malignancy, largely composed of extra-thoracic advanced stage cancers, with possible different implications in patients without extra-thoracic spread.